Articles tagged with Drug Resistance
Researchers found that chloroquine-resistant parasites arose in multiple geographic locations and rapidly spread across continents, contradicting long-held theories. The genetic diversity of the malaria parasite suggests it has evolved over a timeframe coincident with human population expansion out of Africa.
The new treatment guidelines emphasize the use of CD4 cell counts as a primary indicator for starting therapy, rather than plasma HIV RNA levels. The guidelines also highlight the importance of patient adherence and regular monitoring of viral load and CD4 cell counts to ensure successful treatment.
A multi-center trial shows that new drug combinations, including two protease inhibitors, can significantly lower virus counts in patients with moderately advanced immunodeficiency. The study found that 31% of patients could achieve detectable viral loads with regimens containing four or five new drugs.
A study published in JAMA found that nearly 28% of newly infected people have a strain of HIV resistant to at least one class of antiretroviral drugs, highlighting the need for new treatment options. The research also shows that drug-resistant viruses take longer to control with current treatments.
Northwestern researcher Robert L. Murphy calls for simplified, less toxic HIV therapies due to complex regimens and adverse effects. He discusses potential new treatments like atazanavir, a single-daily-dose protease inhibitor with minimal side effects.
Researchers found that drug combinations significantly reduced HIV levels in untreated patients, with at least 75% achieving a viral load of less than 400 copies/mL after 48 weeks. The study used three different drug combinations and found impressive changes in viral loads across all groups.
Researchers found that genetic variations in HIV-A and HIV-C proteases make it harder for antiviral drugs to work. The study's findings have negative implications for long-term efficacy of therapies in patients infected with African subtypes.
Research suggests African HIV subtypes exhibit higher fitness in protease inhibitors due to natural mutations, leading to faster therapy failure. The findings support broader focus on HIV drug development beyond the B subtype.
Researchers have discovered a new drug combination that outperforms existing treatments in patients with no prior treatment. The lopinavir-ritonavir combination demonstrates superior virus inhibition and reduces the risk of resistance, offering a more convenient regimen for patients.
Two new drugs, PKC412 and CT53518, have shown promising results in treating acute myeloid leukemia (AML), a deadly form of blood cancer. The drugs, which target the FLT3 receptor, have been effective in killing leukemia cells and prolonging survival in mouse models.
A new treatment combination of amodiaquine and artesunate has shown high cure rates for uncomplicated malaria in children under 11 years old. The study found that the treatment was more effective than amodiaquine alone, with higher cure rates in Gabon compared to Kenya and Senegal.
A new research study identifies a protein called PTP1B that helps overcome leptin resistance, a common issue in obese individuals. The knockout mice lacking PTP1B displayed increased energy expenditure and were resistant to high-fat diets.
Scientists have found a potential mechanism for obesity resistance in mice lacking the fat-making enzyme DGAT1. These mice are more sensitive to leptin and insulin, leading to lower tissue triglyceride levels and increased sensitivity to insulin, resulting in weight loss despite high-fat diets.
Researchers found that a combination of targeted therapies can effectively inhibit tumor growth in prostate cancer. Using different drugs after resistance occurred inhibited tumor growth, suggesting multiple treatments may be needed to manage the disease. This approach is similar to how advanced breast cancer is treated today.
Scientists have developed a new compound, TAS-108, which inhibits the growth of tamoxifen-resistant breast tumours. It works by recruiting a co-repressor to help inhibit oestrogen receptors, making it more effective than other anti-oestrogens.
The study found TMC125 effective against highly NNRTI-resistant HIV strains in patients failing treatment. The drug showed no signs of resistance development and was well-tolerated during the trial.
Researchers at Duke University Medical Center have traced cellular pathways that enhance the action of antifungal drugs used to treat fungal infections in people with compromised immune systems. Combining fluconazole with cyclosporin or FK506 was found to potently kill fungal cells, and the team elucidated the molecular targets involved.
UCSF scientists have demonstrated in animals how morphine's potent painkilling powers can be sustained without increasing dosages. By pairing morphine with an opioid that facilitates endocytosis, they showed that the natural cellular process can arrest the pattern of tolerance to morphine.
Researchers at NIAID and NCI discovered a quick and simple method to assess drug efficacy by measuring viral load after just one week of therapy. This approach has the potential to prevent HIV drug resistance and improve treatment outcomes for patients.
A recent study has identified over 100 yeast genes that provide protection against radiation, revealing new insights into human genetic resistance to environmental stressors. The findings also suggest potential targets for the development of more effective anti-cancer drugs.
Researchers have found a new antimalarial drug combination to be effective in treating falciparum malaria, the most severe form of the disease. In a study conducted in Tanzania, 93% of children were cleared of parasites after treatment with chlorproguanil-dapsone, compared to just 39% on standard pyrimethamine-sulfadoxine.
Researchers predict that 42% of all HIV cases will be drug-resistant by 2005, mainly due to the conversion of drug-sensitive cases during antiretroviral therapy. The study recommends four epidemic-control strategies to minimize prevalence and transmission of drug-resistant HIV.
A recent outbreak of sleeping sickness in eastern Uganda may be attributed to livestock movement from another part of the country where the disease is endemic. The study found that over 50% of cattle traded at the market originated from areas with the disease, and that distance to the market was a significant risk factor for sleeping s...
AIDS researchers urge collaboration to develop new treatments for drug-resistant HIV patients, who represent 30% of treated cases in the US. The lack of effective therapies sets the stage for a dangerous epidemic of drug-resistant HIV.
A study found that a specific mutation in the human MDR1 gene affects P-glycoprotein expression, leading to decreased effectiveness of HIV-1 protease inhibitors in West Africans and African Americans compared to Caucasians. This could have significant implications for drug treatment in these populations.
A retrospective study of 681 HIV-positive patients found that Virco's VirtualPhenotype? and Antivirogram? resistance tests accurately predicted treatment outcomes. Patients receiving three or four active drugs experienced significant reductions in viral load and increases in CD4 cell counts.
Researchers at Johns Hopkins Medicine found that HAART suppresses viral replication and mutation, delaying the onset of AIDS. The study used genetic signatures to track HIV-1 activity in 20 participants on HAART for at least 25 months.
Researchers found that HBV polymerase mutations can restore viral replication rate while maintaining drug resistance, affecting treatment efficacy. Entecavir proved effective against even the most vigorous drug-resistant mutants, offering a promising alternative to lamivudine.
A growing global problem: Bacterial resistance to antibiotics is on the rise, with penicillin and macrolide antibiotics showing high levels of resistance. Telithromycin, a new ketolide antibiotic, has shown promise in combating treatment-resistant respiratory tract infections.
Researchers have identified a single gene on chromosome 7 of Plasmodium falciparum that makes the most deadly malaria parasite resistant to chloroquine. The pfcrt gene is associated with chloroquine resistance in parasite lines from Asia, Africa, and South America.
A study by University of Toronto researchers found that repeated exposure to azole drugs can lead to the development of drug-resistant yeast infections. About 75% of women between 18 and 35 will experience at least one yeast infection caused by Candida albicans, a common type of yeast fungus.
The study found that 27.2% of HIV patients were resistant to all three classes of drugs, while 29.1% had resistance to two classes and 21.9% were resistant to one. This underscores the importance of resistance testing for treatment decision-making in HIV clinical practice.
The international panel established recommendations for drug resistance testing in treating HIV failure and pregnant women. This guidance aims to optimize the use of these tests in designing effective drug therapies.
A preliminary study found that 38% of HIV-positive people in low-income hotels took over 90% of their medication, adhering well to combination anti-viral therapy. The researchers also discovered a close relationship between medication adherence and viral suppression, with levels of HIV doubling for every 10% of missed pills.
A new model predicts that expanding potent HIV therapies will limit infections and AIDS deaths, even with increased risk behavior and drug resistance. The model shows that treating more HIV-infected men will reduce infection rates and deaths below what they would be without treatment.
A new botulinum toxin type B medication has shown significant improvements in pain, disability, and disease severity in cervical dystonia patients. The treatment's benefits lasted for 12-16 weeks with no serious adverse side effects reported.
Researchers at St. Jude Children's Research Hospital found the gene MRP4 is responsible for drug resistance in HIV patients, leading to lower drug concentrations and increased virus replication. This discovery could lead to developing new therapies to fight HIV infection and other diseases.
Researchers at the University of Maryland Medical Center have discovered a cancer resistance protein that rapidly pumps out chemotherapy from breast cancer cells. This finding may lead to new strategies to reverse resistance to cancer-fighting drugs, improving treatment outcomes for patients.
Researchers suggest that genetic remnants of an ancient virus incorporated into human DNA may assist the AIDS virus in evading anti-drug treatments. Studies found that a specific enzyme from this endogenous virus gene can complement HIV-1 protease activity, making it resistant to current drugs.
Researchers at Brandeis University have pinpointed a genetic repressor that can transform diphtheria into a lethal parasite. The discovery could lead to a novel class of antibiotics that prevent bacterial virulence without inducing resistance.
A study by UNC researchers confirms the presence of mutated, drug-resistant human immunodeficiency virus in the semen of men taking antiviral medications. The study found that if men do not have adequate suppression of their virus, they are likely to shed drug-resistant strains of HIV in their genital secretions.
The international panel emphasizes that blood tests measuring HIV levels and CD4 cells should guide treatment decisions, rather than resistance testing. The panel also highlights the limitations of current resistance assays and recommends further epidemiological studies to monitor resistant strain prevalence.
Scientists have discovered that Helicobacter pylori resistance to metronidazole is caused by mutation in the rdxA gene. This gene codes for an enzyme that converts metronidazole into hydroxylamine, a mutagen and cancer-causing chemical.
Researchers found glioblastoma multiforme tumors resistant to procarbazine exhibited defects in mismatch repair, leading to drug resistance. The study may lead to more effective treatment of GBM, a common and virulent brain tumor.
Researchers at Johns Hopkins have found that spending more time and money on strict drug regimens saves money in the long run. The cost-effective strategy, called directly observed therapy (DOT), cures more people sooner and decreases the risk of developing TB germs resistant to treatment.